Overview
Corporate Profile
T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. For more information, please visit www.t2biosystems.com.
Stock Quote
| (Common Stock) | ||
|---|---|---|
| Exchange | (US Dollar) | |
| Price | ||
| Change (%) | ||
| Volume | ||
Minimum 15 minutes delayed. Source: LSEG
Recent News
| Date | Title | ||
|---|---|---|---|
|
12/18/24
|
Summary ToggleT2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor |
|
Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis tests LEXINGTON, Mass. , Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the |
|
12/17/24
|
Summary ToggleT2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally |
|
Milestone demonstrates the growing customer adoption of the Company’s proprietary technology LEXINGTON, Mass. , Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it |
|
12/16/24
|
Summary ToggleT2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. |
|
LEXINGTON, Mass. , Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest |
|
12/09/24
|
Summary ToggleT2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens |
|
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass. , Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of |